How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?

被引：1
|
作者：
Takigawa, Nagio [1 ]
机构：
[1] Kawasaki Med Sch, Dept Gen Internal Med 4, Kita Ku, 2-6-1 Nakasange, Okayama 7008505, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
OPEN-LABEL; ACQUIRED-RESISTANCE; CRIZOTINIB; CHEMOTHERAPY; IDENTIFICATION; INHIBITION; MUTATIONS; CERITINIB;
D O I：
10.1016/j.jtho.2018.07.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1438 / 1440
页数：3
相关论文
共 50 条
  • [31] Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
    Yu, Hui
    Sun, Si
    Hu, Xingjiang
    Xia, Jinjing
    Wang, Jialei
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2019, 12 : 6481 - 6495
  • [32] Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer
    Koizumi, Tomonobu
    Fukushima, Toshirou
    Tatai, Toshiharu
    Kobayashi, Takashi
    Sekiguchi, Nodoka
    Sakamoto, Akiyuki
    Sasaki, Shigeru
    LUNG CANCER, 2015, 88 (01) : 112 - 113
  • [33] Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
    Morcos, Peter N.
    Nueesch, Eveline
    Jaminion, Felix
    Guerini, Elena
    Hsu, Joy C.
    Bordogna, Walter
    Balas, Bogdana
    Mercier, Francois
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 129 - 138
  • [34] A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature
    De Smedt, Fabian
    Dessy, Frederique
    Carestia, Luciano
    Baldin, Pamela
    Nana, Frank Aboubakar
    Clapuyt, Philippe
    Boon, Veronique
    Amant, Frederic
    Gziri, Mina Mhallem
    ONCOLOGY LETTERS, 2023, 25 (02)
  • [35] Unveiling Hidden MET-Mediated Primary Alectinib Resistance in ALK-Positive Non-Small Cell Lung Cancer
    Le, A.
    Tyler, L.
    Davies, K.
    Kondo, K.
    Pacheco, J.
    Merrick, D.
    Aisner, D.
    Camidge, D. R.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S555 - S556
  • [36] Treatment of brain metastases in ALK-positive non-small cell lung cancer
    Ceddia, Serena
    Codacci-Pisanelli, Giovanni
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 165
  • [37] Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
    Mogenet, Alice
    Tomasini, Pascale
    Greillier, Laurent
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S383 - S386
  • [38] The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
    Kaczmar, John
    Mehra, Ranee
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 236 - 241
  • [39] Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
    Choo, Joan Rou-En
    Soo, Ross A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (04) : 233 - 240
  • [40] Efficacy and safety study with alectinib in advanced ALK-positive non-small-cell lung cancer
    Fernandez Madrigal, Laura
    Garcia Samblas, Victoria
    Amor Urbano, Maria
    Inoriza, Angel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345